SCHEMBL21074870

SCHEMBL21074870

Cc1ccc(OC(C)CCC(C)C)cc1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 2/20 0.39
▸ KMT2A Q03164 3/20 0.38
▸ MAPT P10636 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ NLRP1 Q9C000 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ SIGMAR1 Q99720 2/20 0.36
▸ MTNR1A P48039 1/20 0.35
▸ MTNR1B P49286 1/20 0.35
▸ PPARG P37231 2/20 0.35
▸ PPARA Q07869 2/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ CYP3A4 P08684 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ TEAD4 Q15561 1/20 0.34
▸ CNR2 P34972 1/20 0.34
▸ SCN5A Q14524 1/20 0.34
▸ SCN2A Q99250 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19188889 0.82 ABL1 (0.41) ACHEKMT2AMAPTALDH1A1NLRP1
SCHEMBL29690390 0.81 KMT2A (0.42) ACHEKMT2AMAPTALDH1A1NLRP1
SCHEMBL9869523 0.80 ACHE (0.44) ACHEKMT2AMAPTALDH1A1NLRP1
SCHEMBL12431876 0.80 GPR88 (0.45) ACHEKMT2AMAPTALDH1A1NLRP1
SCHEMBL1454910 0.79 SIGMAR1 (0.36) ACHEKMT2AMAPTALDH1A1NLRP1
SCHEMBL6851302 0.79 SLC7A5 (0.39) ACHEKMT2AMAPTALDH1A1NLRP1
SCHEMBL14420323 0.79 KMT2A (0.36) ACHEKMT2AMAPTALDH1A1NLRP1
SCHEMBL8263616 0.78 ACHE (0.42) ACHEKMT2AMAPTALDH1A1NLRP1
SCHEMBL13064360 0.78 ACHE (0.42) ACHEKMT2AMAPTALDH1A1NLRP1
SCHEMBL14828692 0.78 MCHR1 (0.42) ACHEKMT2AMAPTALDH1A1NLRP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210330642-A1 METHOD FOR TREATING CANCER BY COMBINATION OF IAP INHIBITOR AND MODULATOR OF IMMUNE CHECKPOINT MOLECULE ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2021-10-28 — — US disclosed
US-10756444-B2 Scanning antenna and scanning antenna production method SHARP KABUSHIKI KAISHA (JP) 2020-08-25 — — US disclosed
US-20190173198-A1 SCANNING ANTENNA AND SCANNING ANTENNA PRODUCTION METHOD SHARP KABUSHIKI KAISHA (JP) 2019-06-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210330642-A1 METHOD FOR TREATING CANCER BY COMBINATION OF IAP INHIBITOR AND MODULATOR OF IMMUNE CHECKPOINT MOLECULE XIAP, BIRC5, BIRC2 ACHE 2541/4885KMT2A 2133/4885MAPT 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback